Finerenone vs HRS-1780
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Kidney Disease
Shared mechanism: Mineralocorticoid receptor · full Chronic Kidney Disease pipeline
Finerenone · Kerendia
Marketed by Bayer
NCT02540993 · Phase 3 · completed
The trial was randomized, quadruple-blind, placebo-controlled, and large, with 5,734 participants randomized nearly equally between finerenone and placebo. Its hard clinical kidney endpoint was met: 504 participants receiving finerenone versus 600 receiving placebo experienced the primary outcome, with a statistically significant hazard ratio of 0.825 (p=0.0014).
Next expected readout: November 2026 · NCT06954090 (registry estimate)
Reported efficacy
Mean rate of change as measured by the total slope of eGFR from baseline to Month-32. (From baseline to month 32): Total eGFR slope, baseline to month 32 (FIND-CKD): -3.3 mL/min/1.73m2/year finerenone vs -4.0 mL/min/1.73m2/year placebo; between-group difference 0.7 mL/min/1.73m2/year (95% CI 0.3-1.1; p<0.001) (met)
Result source: NCT05047263
HRS-1780
Developed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: April 2030 · NCT07419828 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Chronic Kidney Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Finerenone | HRS-1780 |
|---|---|---|
| Kidney composite outcome | —Not posted · NCT05047263 | —Trial running · NCT07419828 |
| UACR, % change | —Not posted · NCT05047263 | —Trial running · NCT07419828 |
| eGFR slope | —Not posted · NCT05047263 | —Trial running · NCT07419828 |
| Haemoglobin, change | —Not posted · NCT05047263 | —Trial running · NCT07419828 |
Kidney composite outcome
- Finerenone
- —Not posted · NCT05047263
- HRS-1780
- —Trial running · NCT07419828
UACR, % change
- Finerenone
- —Not posted · NCT05047263
- HRS-1780
- —Trial running · NCT07419828
eGFR slope
- Finerenone
- —Not posted · NCT05047263
- HRS-1780
- —Trial running · NCT07419828
Haemoglobin, change
- Finerenone
- —Not posted · NCT05047263
- HRS-1780
- —Trial running · NCT07419828
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
HRS-1780: no structured comparison results are available for Chronic Kidney Disease.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Finerenone: 4 of 4 rows · HRS-1780: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Finerenone |
|---|---|
| Dropout rate | 1.5%a NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 10 more results—Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination —Finerenone Group NCT05254002 · Phase 2 · registry result, not featured evidence 12.1%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence 1% NCT05013008 · Phase 2 · registry result, not featured evidence 21.2%10-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 24.8%15-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 30.1%2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 26.1%5-10 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 27.2%7.5-15 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence —2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —a NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 10 more results—Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination —Finerenone Group NCT05254002 · Phase 2 · registry result, not featured evidence 4.8%Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence — NCT05013008 · Phase 2 · registry result, not featured evidence 10.6%10-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 12.7%15-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 12.7%2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 15.8%5-10 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 14.8%7.5-15 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence —2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 31.9%a NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 10 more results7.1%Finerenone + Empagliflozin Group NCT05254002 · Phase 2 · registry result, not featured evidence · combination 6.1%Finerenone Group NCT05254002 · Phase 2 · registry result, not featured evidence —Finerenone and Empagliflozin NCT05254002 · Phase 2 · registry result, not featured evidence — NCT05013008 · Phase 2 · registry result, not featured evidence 27.2%10-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 35%15-20 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence —2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 28.8%5-10 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 31.1%7.5-15 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence 41.9%2.5-5 mg OD NCT01807221 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | a hyperkalaemia 14.9% (placebo 7.5%) nasopharyngitis 8.5% (placebo 8.8%) anaemia 7.1% (placebo 6.3%) NCT02540993 · Phase 3 · monotherapy · Chronic Kidney Disease, Type 2 Diabetes · phase 3 show 7 more resultshyperkalaemia 9.3% glomerular filtration rate decreased 6.3% diarrhoea 3.4% NCT05254002 · Phase 2 · registry result, not featured evidence · combination hyperkalaemia 10.2% glomerular filtration rate decreased 4.2% diarrhoea 3.4% NCT05254002 · Phase 2 · registry result, not featured evidence 10-20 mg OD hypokalaemia 8.3% renal impairment 4.7% cardiac failure 4.1% NCT01807221 · Phase 2 · registry result, not featured evidence 15-20 mg OD hypokalaemia 10.4% cardiac failure 6.1% dyspnoea 6.1% NCT01807221 · Phase 2 · registry result, not featured evidence 5-10 mg OD hypokalaemia 12.9% hypotension 6.7% cardiac failure 6.1% NCT01807221 · Phase 2 · registry result, not featured evidence 7.5-15 mg OD hypokalaemia 9% hypotension 6.6% diarrhoea 6% NCT01807221 · Phase 2 · registry result, not featured evidence 2.5-5 mg OD hypokalaemia 11.6% cardiac failure 8.1% dyspnoea 7% NCT01807221 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 10 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Finerenone
show 3 more results
show 4 more results
show 14 more results
show 4 more results
show 9 more results
show 9 more results
show 4 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Finerenone's landscape · HRS-1780's landscape